P2RX7 and neoplasm: CD39 blockade augmented exATP/P2X7-mediated pro-inflammatory anti-tumor response and release of IL-18, which facilitated increased infiltration of intra-tumor Teff cells and overturned anti-PD-1 resistance (349).